Go to
current issue
-
Top product forecasts for 2020 Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-15 Lisa Urquhart
Discover the world’s best science and medicine | Nature.com
-
Publisher Correction: Breast cancer drug approvals by the US FDA from 1949 to 2018 Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-14 Chandra P. Leo; Cornelia Leo; Thomas D. Szucs
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Sorafenib analogue combats MRSA Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-13 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Improving immunotherapy Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-13 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Hydrogel fights infection and inflammation Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-13 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Saving hearts with HDAC inhibition Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-13 Stacey-Lynn Paiva
Discover the world’s best science and medicine | Nature.com
-
Driving CARs to last Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-13 Megan Cully
Discover the world’s best science and medicine | Nature.com
-
bnAbs for HIV: shepherding towards improbable mutations Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-13 Alexandra Flemming
Discover the world’s best science and medicine | Nature.com
-
Biopharma dealmaking in 2019 Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-10 Amanda Micklus; Patricia Giglio
Discover the world’s best science and medicine | Nature.com
-
Restoring FGF21 reverses pancreatitis Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-10 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-08 Erik Tambuyzer; Benjamin Vandendriessche; Christopher P. Austin; Philip J. Brooks; Kristina Larsson; Katherine I. Miller Needleman; James Valentine; Kay Davies; Stephen C. Groft; Robert Preti; Tudor I. Oprea; Marco Prunotto
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cure Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-08 Gregory C. Fanning; Fabien Zoulim; Jinlin Hou; Antonio Bertoletti
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Value of 2019 FDA approvals: back to the recent average Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-07 Mathias Baedeker; Michael Ringel; Ulrik Schulze
Discover the world’s best science and medicine | Nature.com
-
NK cells for cancer immunotherapy Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-06 Noriko Shimasaki; Amit Jain; Dario Campana
-
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-03 S. Depil; P. Duchateau; S. A. Grupp; G. Mufti; L. Poirot
-
Advances in oral peptide therapeutics Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-17 Daniel J. Drucker
-
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-13 Erik Tambuyzer; Benjamin Vandendriessche; Christopher P. Austin; Philip J. Brooks; Kristina Larsson; Katherine I. Miller Needleman; James Valentine; Kay Davies; Stephen C. Groft; Robert Preti; Tudor I. Oprea; Marco Prunotto
-
Andy Plump Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-10 Asher Mullard
With Takeda’s US$62 billion acquisition of Shire in 2018, the Japanese firm scored a spot as a top 10 pharmaceutical firm. But well before the deal was even on the radar, President of R&D Andy Plump and CEO Christophe Weber were already working to transform the company. Once a small-molecule specialist, it is now embracing new modalities to be better positioned to follow the biology of disease. Once internally focused, it is now partnering whenever possible both to bring compelling new projects in and to let promising assets out. And Plump, now celebrating 5 years at the firm, is ready to showcase Takeda’s new look. He spoke with Asher Mullard about Takeda’s plans to leapfrog competitors in immuno-oncology, cellular therapy, rare diseases, gene therapy and more.
-
Upcoming market catalysts in Q1 2020 Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-09 Jenny Tan
Discover the world’s best science and medicine | Nature.com
-
Sickle cell disease celebration Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-05 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
RNAi agents score an approval and drive an acquisition Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-05 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Rethinking drug design in the artificial intelligence era Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-04 Petra Schneider, W. Patrick Walters, Alleyn T. Plowright, Norman Sieroka, Jennifer Listgarten, Robert A. Goodnow, Jasmin Fisher, Johanna M. Jansen, José S. Duca, Thomas S. Rush, Matthias Zentgraf, John Edward Hill, Elizabeth Krutoholow, Matthias Kohler, Jeff Blaney, Kimito Funatsu, Chris Luebkemann, Gisbert Schneider
-
Learning from worms to kill Gram-negative bacteria Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-04 Stacey-Lynn Paiva
Discover the world’s best science and medicine | Nature.com
-
Decoy receptor targets lung cancer Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-03 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
GPR146 inhibition protects against atherosclerosis Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-03 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Lowering mutant huntingtin protein Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-03 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Reversing resistance to MRSA Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-03 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
PKMYT1: a forgotten member of the WEE1 family Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-26 Christopher R. M. Asquith, Tuomo Laitinen, Michael P. East
Discover the world’s best science and medicine | Nature.com
-
Cancer cells’ loss is T cells’ gain Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-22 M. Teresa Villanueva
Discover the world’s best science and medicine | Nature.com
-
The patent landscape of inflammasome modulators Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-21 Benjamin Leung, Drew Lowery
Discover the world’s best science and medicine | Nature.com
-
Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-20 Richard J. Weaver, Eric A. Blomme, Amy E. Chadwick, Ian M. Copple, Helga H. J. Gerets, Christopher E. Goldring, Andre Guillouzo, Philip G. Hewitt, Magnus Ingelman-Sundberg, Klaus Gjervig Jensen, Satu Juhila, Ursula Klingmüller, Gilles Labbe, Michael J. Liguori, Cerys A. Lovatt, Paul Morgan, Dean J. Naisbitt, Raymond H. H. Pieters, Jan Snoeys, Bob van de Water, Dominic P. Williams, B. Kevin Park
-
Breast cancer drug approvals by the US FDA from 1949 to 2018 Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-20 Chandra P. Leo, Cornelia Leo, Thomas D. Szucs
Discover the world’s best science and medicine | Nature.com
-
A decade of optimizing drug development for rare neuromuscular disorders through TACT Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-19 Kathryn R. Wagner, Annamaria De Luca, Didier Caizergues, James Dowling, Nathalie Goemans, Heather Gordish-Dressman, Miranda D. Grounds, Michael Kelly, Anna Mayhew, Elizabeth M. McNally, Tracey Zoetis, Joanne Lee, Cathy Turner, Dominic J. Wells, Cristina Csimma, Volker Straub
This year marks the tenth anniversary of the TREAT-NMD Advisory Committee for Therapeutics (TACT), a group of multidisciplinary experts that evaluates drug development programmes for rare neuromuscular diseases and identifies pitfalls. Here, we discuss the experience with TACT based on its reviews of more than 50 applications and its potential as a model for other rare disorders.
-
Dumping STAT3 in the trash Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-15 Stacey-Lynn Paiva
Discover the world’s best science and medicine | Nature.com
-
Phages fight alcoholic hepatitis Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-15 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Reshma Kewalramani Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-12 Asher Mullard
Vertex’s goal over much of the past decade has been on treating cystic fibrosis, targeting the dysfunctional CFTR chloride channel at the root of the disease. Following the speedy approval in October of its triple combination therapy Trikafta, nearly 90% of people with cystic fibrosis now stand to benefit from the firm’s CFTR potentiators and correctors. With this landmark success in hand — and the lucrative market it has opened up — the company is now in the process of broadening its horizons. In April 2020, current CMO Reshma Kewalramani will step up to the CEO role to oversee the transition. She spoke with Asher Mullard about the lessons the company has learned from cystic fibrosis drug development and its future R&D plans.
-
Cracking KRAS Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-12 Asher Mullard
Five anti-cancer KRAS inhibitors, with three different modes of action, are in the clinic. More are on the way.
-
Synthetic lethality as an engine for cancer drug target discovery Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-11 Alan Huang, Levi A. Garraway, Alan Ashworth, Barbara Weber
-
Cloud-based data systems in drug regulation: an industry perspective Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-11 Andrew S. Robertson, Hilary Malone, Fabio Bisordi, Helen Fitton, Carlos Garner, Stacy Holdsworth, Peter Honig, Mathias Hukkelhoven, Robert Kowalski, Sandra Milligan, Liza O’Dowd, Khyati Roberts, Michelle Rohrer, Jerry Stewart, Mark Taisey, Roopal Thakkar, Karin Van Baelen, Max Wegner
Cloud-based systems for data submitted by sponsors to drug regulatory agencies have the potential to accelerate drug development, streamline regulatory review and enhance regulatory decision-making. Here, we provide a vision for integrating cloud-enabled practices in drug regulation globally.
-
Treg conversion dampens autoimmunity Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-07 Megan Cully
Discover the world’s best science and medicine | Nature.com
-
Double boost for mRNA cancer vaccines Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-07 M. Teresa Villanueva
Discover the world’s best science and medicine | Nature.com
-
NIH launches open science Alzheimer initiative Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-06 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Arvinas’s PROTACs pass first safety and PK analysis Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-06 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Affordable HIV and sickle cell disease gene therapies Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-06 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Mechanism of RNA splicing modifiers in SMA Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-05
Discover the world’s best science and medicine | Nature.com
-
How many rare diseases are there? Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-05 Mellisa Haendel, Nicole Vasilevsky, Deepak Unni, Cristian Bologa, Nomi Harris, Heidi Rehm, Ada Hamosh, Gareth Baynam, Tudor Groza, Julie McMurry, Hugh Dawkins, Ana Rath, Courtney Thaxon, Giovanni Bocci, Marcin P. Joachimiak, Sebastian Köhler, Peter N. Robinson, Chris Mungall, Tudor I. Oprea
A lack of robust knowledge of the number of rare diseases and the number of people affected by them limits the development of approaches to ameliorate the substantial cumulative burden of rare diseases. Here, we call for coordinated efforts to more precisely define rare diseases.
-
Patient-derived organoids predict chemotherapy response Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-05
Discover the world’s best science and medicine | Nature.com
-
Targeting IL-11 in idiopathic pulmonary fibrosis Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-05
Discover the world’s best science and medicine | Nature.com
-
Using utrophin to treat DMD Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-05
Discover the world’s best science and medicine | Nature.com
-
Trends in clinical development for PD-1/PD-L1 inhibitors Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-11-04 Jia Xin Yu, Jeffrey P. Hodge, Cristina Oliva, Svetoslav T. Neftelinov, Vanessa M. Hubbard-Lucey , Jun Tang
Discover the world’s best science and medicine | Nature.com
-
Targeted protein degradation: expanding the toolbox Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-30 Matthieu Schapira, Matthew F. Calabrese, Alex N. Bullock, Craig M. Crews
-
Adding to the senolytic arsenal Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-25 Stacey-Lynn Paiva
Discover the world’s best science and medicine | Nature.com
-
Chemical inhibitors make their RNA epigenetic mark Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-24 Megan Cully
RNA epigenetic drug development enters a new era, as companies start revealing targets and evidence of preclinical efficacy.
-
Expanding the gene editing landscape Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-22 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
FDA new drug approvals in Q3 2019 Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-11 Lisa Urquhart
Discover the world’s best science and medicine | Nature.com
-
The great escape: tumour cell plasticity in resistance to targeted therapy Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-10 Soufiane Boumahdi, Frederic J. de Sauvage
-
Roger Perlmutter Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-07
In 2009, Merck & Co.’s PD1-blocking antibody pembrolizumab was in development limbo. A decade on, the immuno-oncology drug is Merck’s crown jewel, with more than 20 approvals in 15 tumour types and revenues that are expected to reach US$10 billion this year. For Roger Perlmutter — an immunologist, president of Merck Research Laboratories and executive vice-president of Merck & Co. — this success was not always a sure thing. On the fifth anniversary of the FDA’s approval of pembrolizumab, he spoke with Asher Mullard about remaining immuno-oncology opportunities and questions.
-
FDA approves oral version of diabetes biologic Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-04 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Cancer stem cell candidate Rova-T discontinued Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-04 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
PARP inhibitor pick-me-up Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-10-04 Asher Mullard
Discover the world’s best science and medicine | Nature.com
京公网安备 11010802027423号